U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H26N2O4
Molecular Weight 370.4421
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Samidorphan

SMILES

NC(=O)C1=CC=C2C[C@H]3N(CC4CC4)CC[C@@]5(CC(=O)CC[C@@]35O)C2=C1O

InChI

InChIKey=RYIDHLJADOKWFM-MAODMQOUSA-N
InChI=1S/C21H26N2O4/c22-19(26)15-4-3-13-9-16-21(27)6-5-14(24)10-20(21,17(13)18(15)25)7-8-23(16)11-12-1-2-12/h3-4,12,16,25,27H,1-2,5-11H2,(H2,22,26)/t16-,20-,21-/m1/s1

HIDE SMILES / InChI

Molecular Formula C21H26N2O4
Molecular Weight 370.4421
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Samidorphan, which was developed by Alkermes, is an opioid receptor antagonist that has been co-formulated with olanzapine into a single-dose oral tablet to mitigate the risk of weight gain while providing the therapeutic effect of olanzapine. In June 2021, the Food and Drug Administration (FDA) approved Lybalvi (olanzapine/samidorphan) for indications including treatment of adults with schizophrenia and/or bipolar I disorder (acute manic episodes or acute episodes with mixed features).

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Lybalvi

Approved Use

Schizophrenia in adults

Launch Date

2021
Primary
Lybalvi

Approved Use

Bipolar I disorder in adults; Acute treatment of manic or mixed episodes as monotherapy and as adjunct to lithium or valproate; Maintenance monotherapy treatment

Launch Date

2021
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
45.1 ng/mL
10 mg 11 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: OLANZAPINE
SAMIDORPHAN plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
11.2 ng/mL
1 mg single, intravenous
dose: 1 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
SAMIDORPHAN plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
4.1 ng/mL
2 mg single, sublingual
dose: 2 mg
route of administration: Sublingual
experiment type: SINGLE
co-administered:
SAMIDORPHAN plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
4.1 ng/mL
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SAMIDORPHAN plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
27.8 ng/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SAMIDORPHAN plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
13.3 ng/mL
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SAMIDORPHAN plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
16.291 ng/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered: OLANZAPINE
SAMIDORPHAN plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
364 ng × h/mL
10 mg 11 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: OLANZAPINE
SAMIDORPHAN plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
27.7 ng × h/mL
1 mg single, intravenous
dose: 1 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
SAMIDORPHAN plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
41.3 ng × h/mL
2 mg single, sublingual
dose: 2 mg
route of administration: Sublingual
experiment type: SINGLE
co-administered:
SAMIDORPHAN plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
39.9 ng × h/mL
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SAMIDORPHAN plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
246 ng × h/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SAMIDORPHAN plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
113.1 ng × h/mL
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SAMIDORPHAN plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
627.907 ng × h/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered: OLANZAPINE
SAMIDORPHAN plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
11 h
10 mg 11 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: OLANZAPINE
SAMIDORPHAN plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
67%
10 mg 11 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: OLANZAPINE
SAMIDORPHAN plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
20 mg 1 times / day multiple, oral
Highest studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Disc. AE: Hypertension, Anxiety...
AEs leading to
discontinuation/dose reduction:
Hypertension (1 pt)
Anxiety (1 pt)
Dizziness (1 pt)
Irritability (1 pt)
Malaise (1 pt)
Suicidal ideation (2 pt)
Sources:
10 mg 1 times / day multiple, oral
Studied dose
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Disc. AE: Schizophrenia, Liver function test abnormal...
AEs leading to
discontinuation/dose reduction:
Schizophrenia (serious, 1%)
Liver function test abnormal (1%)
Sources:
10 mg 1 times / day multiple, oral
Studied dose
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Disc. AE: Somnolence, Neutrophil count decreased...
AEs leading to
discontinuation/dose reduction:
Somnolence (2%)
Neutrophil count decreased (1%)
Weight increased (1%)
Glycosylated hemoglobin increased (1%)
Schizophrenia (1%)
Drug abuse (1%)
Liver function test abnormal (1%)
Fatigue (<1%)
Mental status changes (<1%)
Headache (<1%)
Vomiting (<1%)
Rash (<1%)
Blood creatine phosphokinase increased (<1%)
Rectal hemorrhage (<1%)
Blood creatine increased (<1%)
Pleural effusion (<1%)
Priapism (<1%)
Sources:
30 mg 1 times / day multiple, oral
Studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
healthy, ADULT
Health Status: healthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Disc. AE: Adverse event...
AEs leading to
discontinuation/dose reduction:
Adverse event (0%)
Sources:
10 mg multiple, oral
Recommended
unhealthy
Disc. AE: Viral gastroenteritis, Intentional overdose...
Other AEs: Blood insulin increased...
AEs leading to
discontinuation/dose reduction:
Viral gastroenteritis (1 pt)
Intentional overdose (1 pt)
Dizziness (1 pt)
Blood glucose increased (1 pt)
Suicide attempt (1 pt)
Other AEs:
Blood insulin increased (1 pt)
Sources:
10 mg multiple, oral
Recommended
unhealthy
Disc. AE: Electrocardiogram change, Nausea...
AEs leading to
discontinuation/dose reduction:
Electrocardiogram change (1 pt)
Nausea (1 pt)
Pleural effusion (1 pt)
Dyslipidemia (1 pt)
Dizziness (1 pt)
Seizure (1 pt)
Sources:
AEs

AEs

AESignificanceDosePopulation
Anxiety 1 pt
Disc. AE
20 mg 1 times / day multiple, oral
Highest studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Dizziness 1 pt
Disc. AE
20 mg 1 times / day multiple, oral
Highest studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Hypertension 1 pt
Disc. AE
20 mg 1 times / day multiple, oral
Highest studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Irritability 1 pt
Disc. AE
20 mg 1 times / day multiple, oral
Highest studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Malaise 1 pt
Disc. AE
20 mg 1 times / day multiple, oral
Highest studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Suicidal ideation 2 pt
Disc. AE
20 mg 1 times / day multiple, oral
Highest studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Liver function test abnormal 1%
Disc. AE
10 mg 1 times / day multiple, oral
Studied dose
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Schizophrenia serious, 1%
Disc. AE
10 mg 1 times / day multiple, oral
Studied dose
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Drug abuse 1%
Disc. AE
10 mg 1 times / day multiple, oral
Studied dose
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Glycosylated hemoglobin increased 1%
Disc. AE
10 mg 1 times / day multiple, oral
Studied dose
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Liver function test abnormal 1%
Disc. AE
10 mg 1 times / day multiple, oral
Studied dose
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Neutrophil count decreased 1%
Disc. AE
10 mg 1 times / day multiple, oral
Studied dose
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Schizophrenia 1%
Disc. AE
10 mg 1 times / day multiple, oral
Studied dose
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Weight increased 1%
Disc. AE
10 mg 1 times / day multiple, oral
Studied dose
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Somnolence 2%
Disc. AE
10 mg 1 times / day multiple, oral
Studied dose
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Blood creatine increased <1%
Disc. AE
10 mg 1 times / day multiple, oral
Studied dose
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Blood creatine phosphokinase increased <1%
Disc. AE
10 mg 1 times / day multiple, oral
Studied dose
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Fatigue <1%
Disc. AE
10 mg 1 times / day multiple, oral
Studied dose
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Headache <1%
Disc. AE
10 mg 1 times / day multiple, oral
Studied dose
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Mental status changes <1%
Disc. AE
10 mg 1 times / day multiple, oral
Studied dose
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Pleural effusion <1%
Disc. AE
10 mg 1 times / day multiple, oral
Studied dose
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Priapism <1%
Disc. AE
10 mg 1 times / day multiple, oral
Studied dose
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Rash <1%
Disc. AE
10 mg 1 times / day multiple, oral
Studied dose
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Rectal hemorrhage <1%
Disc. AE
10 mg 1 times / day multiple, oral
Studied dose
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Vomiting <1%
Disc. AE
10 mg 1 times / day multiple, oral
Studied dose
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Adverse event 0%
Disc. AE
30 mg 1 times / day multiple, oral
Studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
healthy, ADULT
Health Status: healthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Blood insulin increased 1 pt
10 mg multiple, oral
Recommended
unhealthy
Blood glucose increased 1 pt
Disc. AE
10 mg multiple, oral
Recommended
unhealthy
Dizziness 1 pt
Disc. AE
10 mg multiple, oral
Recommended
unhealthy
Intentional overdose 1 pt
Disc. AE
10 mg multiple, oral
Recommended
unhealthy
Suicide attempt 1 pt
Disc. AE
10 mg multiple, oral
Recommended
unhealthy
Viral gastroenteritis 1 pt
Disc. AE
10 mg multiple, oral
Recommended
unhealthy
Dizziness 1 pt
Disc. AE
10 mg multiple, oral
Recommended
unhealthy
Dyslipidemia 1 pt
Disc. AE
10 mg multiple, oral
Recommended
unhealthy
Electrocardiogram change 1 pt
Disc. AE
10 mg multiple, oral
Recommended
unhealthy
Nausea 1 pt
Disc. AE
10 mg multiple, oral
Recommended
unhealthy
Pleural effusion 1 pt
Disc. AE
10 mg multiple, oral
Recommended
unhealthy
Seizure 1 pt
Disc. AE
10 mg multiple, oral
Recommended
unhealthy
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
major
yes (co-administration study)
Comment: Rifampicin decreased AUCinf by 73%, Itraconazole was shown to have only marginal increase (~16% increase in Cmax and ~45% increase in AUC)
Page: 21 | 260 | 272 | 274
minor
minor
no
no
no
no
Tox targets
PubMed

PubMed

TitleDatePubMed
Effects of the Opioid System Modulator, Samidorphan, on Measures of Alcohol Consumption and Patient-Reported Outcomes in Adults with Alcohol Dependence.
2018 Oct
Patents

Sample Use Guides

Schizophrenia: the recommended dosage is 10 mg/10 mg, 15 mg/10 mg (contains 15 mg of olanzapine and 10 mg of samidorphan), or 20 mg/10 mg (contains 20 mg of olanzapine and 10 mg of samidorphan) once daily.
Route of Administration: Oral
In Vitro Use Guide
Using membranes from hMOR-, hKOR and hDOR- CHO cells, competition binding experiments showed that Samidorphan had the highest affinity for the MOR with a Ki value of 0.052 ± 0.0044 nM. [3H]SAM had the highest affinity for the MOR with Kd values of 0.046 ± 0.0027 nM and 0.044 ± 0.0051 nM in TrisHCl and GP buffers, respectively.
Substance Class Chemical
Created
by admin
on Mon Mar 31 20:59:32 GMT 2025
Edited
by admin
on Mon Mar 31 20:59:32 GMT 2025
Record UNII
7W2581Z5L8
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
Samidorphan [INN]
Preferred Name English
Samidorphan
INN   USAN   WHO-DD  
USAN   INN  
Official Name English
ALKS-5461 COMPONENT SAMIDORPHAN
Code English
Samidorphan [WHO-DD]
Common Name English
ALKS-33
Code English
Morphinan-3-carboxamide, 17-(cyclopropylmethyl)-4,14-dihydroxy-6-oxo-
Systematic Name English
Samidorphan [USAN]
Common Name English
RDC-0313
Code English
17-(Cyclopropylmethyl)-4,14-dihydroxy-6-oxomorphinan-3-carboxamide
Systematic Name English
RDC-0313-00
Code English
ALKS 33
Code English
Classification Tree Code System Code
NCI_THESAURUS C681
Created by admin on Mon Mar 31 20:59:32 GMT 2025 , Edited by admin on Mon Mar 31 20:59:32 GMT 2025
Code System Code Type Description
NCI_THESAURUS
C152293
Created by admin on Mon Mar 31 20:59:32 GMT 2025 , Edited by admin on Mon Mar 31 20:59:32 GMT 2025
PRIMARY
SMS_ID
100000164891
Created by admin on Mon Mar 31 20:59:32 GMT 2025 , Edited by admin on Mon Mar 31 20:59:32 GMT 2025
PRIMARY
PUBCHEM
11667832
Created by admin on Mon Mar 31 20:59:32 GMT 2025 , Edited by admin on Mon Mar 31 20:59:32 GMT 2025
PRIMARY
EPA CompTox
DTXSID401030402
Created by admin on Mon Mar 31 20:59:32 GMT 2025 , Edited by admin on Mon Mar 31 20:59:32 GMT 2025
PRIMARY
ChEMBL
CHEMBL426084
Created by admin on Mon Mar 31 20:59:32 GMT 2025 , Edited by admin on Mon Mar 31 20:59:32 GMT 2025
PRIMARY
FDA UNII
7W2581Z5L8
Created by admin on Mon Mar 31 20:59:32 GMT 2025 , Edited by admin on Mon Mar 31 20:59:32 GMT 2025
PRIMARY
EVMPD
SUB179484
Created by admin on Mon Mar 31 20:59:32 GMT 2025 , Edited by admin on Mon Mar 31 20:59:32 GMT 2025
PRIMARY
CAS
852626-89-2
Created by admin on Mon Mar 31 20:59:32 GMT 2025 , Edited by admin on Mon Mar 31 20:59:32 GMT 2025
PRIMARY
INN
9515
Created by admin on Mon Mar 31 20:59:32 GMT 2025 , Edited by admin on Mon Mar 31 20:59:32 GMT 2025
PRIMARY
RXCUI
2559612
Created by admin on Mon Mar 31 20:59:32 GMT 2025 , Edited by admin on Mon Mar 31 20:59:32 GMT 2025
PRIMARY
DRUG BANK
DB12543
Created by admin on Mon Mar 31 20:59:32 GMT 2025 , Edited by admin on Mon Mar 31 20:59:32 GMT 2025
PRIMARY
USAN
XX-137
Created by admin on Mon Mar 31 20:59:32 GMT 2025 , Edited by admin on Mon Mar 31 20:59:32 GMT 2025
PRIMARY
DAILYMED
7W2581Z5L8
Created by admin on Mon Mar 31 20:59:32 GMT 2025 , Edited by admin on Mon Mar 31 20:59:32 GMT 2025
PRIMARY
WIKIPEDIA
SAMIDORPHAN
Created by admin on Mon Mar 31 20:59:32 GMT 2025 , Edited by admin on Mon Mar 31 20:59:32 GMT 2025
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
TARGET->PARTIAL AGONIST
weak partial agonist
BINDING
Ki
TARGET -> INHIBITOR
could have very weak partial agonist activity
BINDING
Ki
TARGET->PARTIAL AGONIST
BINDING
Ki
Related Record Type Details
ACTIVE MOIETY